NACA is a modified version of NAC with one critical difference: the amide group makes it MORE lipophilic, allowing it to cross the blood-brain barrier and cell membranes MUCH more efficiently than standard NAC. Our research shows NACA maintains all of NAC's glutathione-boosting effects while achieving higher intracellular concentrations at lower doses. Animal studies show superior neuroprotection compared to equivalent NAC doses. This is the "next-generation NAC" — same mechanism (glutathione precursor, direct antioxidant), better delivery. Currently niche but gaining research attention for neurodegenerative diseases, TBI, and oxidative stress conditions where brain penetration matters.
NACA (AD4) has the same core chemistry as NAC — the thiol (-SH) group donates electrons to regenerate glutathione and directly scavenge free radicals. The difference is the amide group (-CONH₂) replacing the carboxylic acid (-COOH): (1) increased lipophilicity — the amide group makes NACA more fat-soluble, allowing passive diffusion across lipid bilayer membranes (BBB, mitochondrial membranes, cell membranes) without requiring active transport; (2) higher intracellular accumulation — NACA achieves 3-4x higher intracellular concentrations; (3) maintains deacetylation to cysteine → glutathione synthesis pathway; (4) maintains direct antioxidant thiol activity; (5) better mitochondrial penetration — particularly relevant for neurodegenerative diseases where mitochondrial oxidative damage is central.
Same as NAC — see nac.md. Primary concern: nitroglycerin interaction (potentiates hypotension).
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.